Cumberland Pharmaceuticals Inc. — Net Income by Fiscal Year
17 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/1006d606-0d35-4ed6-b893-81cf4ecdaa4c/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-2.8M | 2025-01-01 – 2025-12-31 | evidence 0001087294-26-000020 |
| FY 2024 | $-6.5M | 2024-01-01 – 2024-12-31 | evidence 0001628280-25-011366 |
| FY 2023 | $-6.3M | 2023-01-01 – 2023-12-31 | evidence 0001628280-24-010725 |
| FY 2022 | $-5.6M | 2022-01-01 – 2022-12-31 | evidence 0001628280-23-007727 |
| FY 2021 | $-3.5M | 2021-01-01 – 2021-12-31 | evidence 0001628280-22-005942 |
| FY 2020 | $-3.3M | 2020-01-01 – 2020-12-31 | evidence 0001628280-21-004654 |
| FY 2019 | $-3.5M | 2019-01-01 – 2019-12-31 | evidence 0001628280-20-003880 |
| FY 2018 | $-7.0M | 2018-01-01 – 2018-12-31 | evidence 0001628280-19-002785 |
| FY 2017 | $-8.0M | 2017-01-01 – 2017-12-31 | evidence 0001628280-18-003034 |
| FY 2016 | $-944.7k | 2016-01-01 – 2016-12-31 | evidence 0001628280-17-002485 |
| FY 2015 | $731.4k | 2015-01-01 – 2015-12-31 | evidence 0001628280-16-012682 |
| FY 2014 | $2.4M | 2014-01-01 – 2014-12-31 | evidence 0001628280-15-001629 |
| FY 2013 | $-2.1M | 2013-01-01 – 2013-12-31 | evidence 0001087294-14-000010 |
| FY 2012 | $5.8M | 2012-01-01 – 2012-12-31 | evidence 0001445305-13-000573 |
| FY 2011 | $5.7M | 2011-01-01 – 2011-12-31 | evidence 0001193125-12-101478 |
| FY 2010 | $2.5M | 2010-01-01 – 2010-12-31 | evidence 0001193125-12-101478 |
| FY 2009 | $3.1M | 2009-01-01 – 2009-12-31 | evidence 0001193125-12-101478 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Cumberland Pharmaceuticals Inc. — all facts · Revenue · Operating Income